CareDx outlines $420M-$444M 2026 revenue target amid solution selling and cell therapy pipeline expansion
Source: SeekingAlpha
2026-02-25 01:28:48 ET
More on CareDx
- CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
- CareDx, Inc. 2025 Q4 - Results - Earnings Call Presentation
- CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy - Slideshow
- CareDx appoints Keith Kennedy as CFO
- CareDx Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
CareDx outlines $420M-$444M 2026 revenue target amid solution selling and cell therapy pipeline expansion
CareDx Inc.
NASDAQ: CDNA
CDNA Trading
-3.24% G/L:
$16.73 Last:
186,222 Volume:
$16.98 Open:
CDNA Latest News
March 05, 2026 04:01:00 pm
CareDx Announces VANTx(TM), an AI?Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
February 24, 2026 05:15:00 pm
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
CDNA Stock Data
$1,055,912,079
49,169,603
1.47%
62
N/A
Medical Diagnostics & Screening
Healthcare
US
Brisbane
